



Living Cell Technologies Ltd

**COMPANY ANNOUNCEMENT
Appendix 4C Quarterly Report**

Quarterly cash flow report period ended 31 December 2008

30 January 2009 – Sydney, Australia, Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the quarterly cash flow report for the quarter ended 31 December 2008. The appendix 4C is attached.

The cash balance at the end of the quarter was \$7,235,292 compared to \$8,670,253 at the end of the quarter to 30 September 2008.

The \$1,434,961 decrease was mainly due to normal operational cash expenditure of \$678,229 compared to \$1,325,758 last quarter. Expenditure included \$887,036 on research and development (\$654,668 last quarter) to meet the supply of higher doses of DiabeCell in the Russia clinical trial. Capital expenditure increased to \$509,498 in the quarter, compared to \$253,822 last quarter, reflecting construction of the new pig facility. Cash received from Government grants increased to \$266,764 from \$60,271.

The ending quarter 31 December saw further data being released to confirm clinical benefit to all patients involved in the clinical trial to date and no remarkable adverse events.

Building consent for the new pig facility was granted and construction commenced. This new facility will be crucial to the supply of DiabeCell for the New Zealand trial in 2009, following approval from New Zealand's Health Minister on 21 October 2008.

In December the company entered into a research agreement with Centocor Research & Development, Inc to carry out research on the use of LCT's proprietary encapsulation technology. This arrangement has the potential for ongoing collaboration and future licensing opportunities.

To focus funds and activities on servicing the clinical trials in Russia and New Zealand Dr Robert Caspari stood down as CEO but remains a director. Dr Paul Tan resumed the CEO role.

-Ends-

For further information:

Dr. Paul L J Tan
COO
Tel: +64 9 270 7940
ptan@lctglobal.com

Mr John Cowan
Finance & Administration Manager
Tel: +64 9 276 2690 ext 739
jcowan@lctglobal.com

Investor and Media Relations
Catie Corcoran
Tel: +61 3 9866 4722
ccorcoran@bcg.com.au

About Living Cell Technologies: www.lctglobal.com

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a bio-certified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients having type 1 diabetes, the Company implants micro-encapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. LCT entered clinical trials for its diabetes product in 2007. The Company is developing treatments for Parkinson's disease and other neurological disorders that involve implantation of micro-encapsulated choroid plexus cells to deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology has the potential for allowing healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to

prevent rejection. LCT also is developing medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will", "project", "believe", "forecast", "expected", "estimated", "targeting", "aiming", "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information as of December 18 2008, and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.